Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Retatrutide has not yet received FDA approval. (Photo credit: AI generated)
Retatrutide, Eli Lilly’s new weight-loss drug, is in the final stages of its clinical trial, and the results seem very promising, the drugmaker said on Thursday. In a news release, they disclosed that the brand-new drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial. While Lilly has not yet filed for approval from the Food and Drug Administration, the pharma giant says that it expects to file this year.
Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. Retatrutide, however, along with GLP-1, mimics glucagon as well, thereby working like a triple agonist. This is unlike Zepbound, which is a double agonist. Researchers said that they have witnessed the impact of semaglutide and tirzepatide. However, Retatrutide's results went beyond the current weight-loss drugs on the market.
Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.
Read more: Meet Retatrutide: The Unapproved Cousin Of Ozempic That Supports Weight Loss Differently
Retatrutide was in the third phase of its trials involving 2,300 obese or overweight participants. While the full results have not yet been released in a medical journal, participants who took the highest dose of the drug lost 28 per cent of their body weight, approximately 70 pounds. Furthermore, nearly half of the participants lost over 30 per cent of their body weight. The trial continued for 80 weeks, and a small group of severely obese patients took the drug for 104 weeks and lost about 85 pounds on average. Alternatively, patients who took high doses of Zepbound lost around 21 per cent of their body weight in 72 weeks. Wegovy users lost about 15 per cent of their weight in 68 weeks.
On the downside, there were some side effects too. Retatrutide users experienced the following side effects:
These have, however, been seen with GLP-1 drugs.
Retatrutide might be the next big weight-loss drug set to hit the market soon. It aims to maximise weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.
Credit: AI generated image
Amid rising cases of the Ebola virus in the Democratic Republic of Congo and Uganda, India and the US have stepped up airport screening.
The latest outbreak, caused by the Bundibugyo Ebola virus, has so far affected nearly 600 people and has caused 139 suspected deaths, as per the latest update by the World Health Organization (WHO). The global health agency has also determined that the deadly outbreak is a “Public Health Emergency of International Concern (PHEIC)”.
India today issued a health advisory for passengers arriving from or transiting through Ebola-affected nations. Passengers with symptoms or exposure history should immediately report to the airport health authorities before immigration clearance.
The advisory, issued by the Directorate General of Health Services (DGHS), specifically mentions travelers coming from the Democratic Republic of Congo, Uganda, and South Sudan, all of which have been categorized as "high-risk countries" by the WHO.
The advisory is displayed at the Delhi airport by the Airport Health Organization (APHO). It advises passengers to watch out for symptoms such as:
It also asks travelers who had direct contact with blood or body fluids of a suspected or confirmed Ebola patient to immediately report to the airport health officer or the health desk.
According to the APHO, any traveler developing symptoms within 21 days of arrival should seek immediate medical care and inform authorities about their travel history.
On Wednesday, India’s Health Secretary Punya Salila Srivastava chaired a high-level review meeting with health secretaries of all states and Union territories to assess preparedness and response measures for Ebola.
Officials clarified that “no case of Ebola has been detected in India so far”.
However, after the WHO declared Ebola a Public Health Emergency, the Indian government has proactively strengthened surveillance and preparedness measures across the country as an abundant precaution, official sources had said. During the meeting, states and Union territories were advised to ensure readiness at all levels.
The 2026 India-Africa Forum Summit, scheduled for May 28 to 31, was also postponed due to the "evolving health situation in parts of Africa", India's Ministry of External Affairs announced today.
The decision was made in recognition of “the importance of ensuring the full participation and engagement of African leaders and stakeholders, and mindful of the emerging public health situation on the continent", said a joint statement issued by the Indian Ministry of External Affairs and the African Union.
Meanwhile, the Centers for Disease Control and Prevention (CDC) has also been enhancing public health screening and traveler monitoring amid a growing Ebola outbreak, and non-US passport holders face entry restrictions if they have been to Uganda, the Democratic Republic of Congo, or South Sudan in the previous 21 days.
“To the American public, the risk to the United States remains low,” said Satish Pillai. “Travelers to the region should avoid contact with sick people, report symptoms immediately, and follow our travel guidance.”
A US missionary doctor infected with the Ebola virus while treating patients in DR Congo has been admitted to Charité hospital in Berlin. The patient was flown to Berlin on a special medical aircraft and then transported to the hospital in a specially designed vehicle escorted by police. The aircraft also carried six other people who had contact with the infected man.
Tedros Adhanom Ghebreyesus said he was “deeply concerned about the scale and speed of the epidemic”. He noted that the numbers are expected to rise given the time taken to detect the virus.
The WHO says it could take up to nine months before a vaccine against this particular species of Ebola is ready.
Two possible "candidate vaccines" against the Bundibugyo species are being developed, but neither has gone through clinical trials yet, WHO advisor Dr. Vasee Moorthy said, according to the BBC.
Speaking to journalists in Geneva, Tedros said 51 cases have been confirmed in the Democratic Republic of Congo — where the first case was reported — and two in neighboring Uganda.
Credit: iStock
A 24-year-old student from West Bengal has reportedly become the first confirmed heatstroke case of the season in India’s national capital.
According to doctors at Dr Ram Manohar Lohia (RML) Hospital, the young man was admitted in critical condition after developing hyperpyrexia — an extremely high body temperature, and altered mental status while travelling by train to the national capital.
"We received our first heatstroke patient at the RML Hospital on the intervening night of May 20-21. The 24-year-old youth from West Bengal was travelling on a train when his health deteriorated,” said Dr Ajay Chauhan, Director Professor of Medicine, at RML, PTI reported.
“He was brought to the hospital in an unconscious state. We took immediate action and tried to cool down his body,” he said, adding that the boy "is admitted to the medicine ward and is still critical".
As per the doctors, the student had no known pre-existing medical condition, and other possible causes of his symptoms were ruled out before heatstroke was diagnosed.
Heatstroke is the most severe form of heat-related illness and is considered a medical emergency. It occurs when the body loses its ability to regulate temperature due to prolonged exposure to extreme heat or dehydration. In most cases, body temperature rises above 104°F (40°C), which can damage the brain, heart, kidneys, and muscles.
“The general features of a patient with heat stroke are: first, his or her body temperature will be very high. It will not be around normal levels like 104, 105, or 106—it will be significantly elevated. Second, the person may be delirious, confused, or even in a state of unconsciousness or coma. The breathing will also be labored,” Dr. Naval Vikram, Professor, Department of Medicine, at the AII India Institute of Medical Sciences (AIIMS), told HealthandMe.
During a heatwave, most patients improve quickly with rest, oral fluids, cooling measures, and moving to a shaded or air-conditioned environment.
"However, if heat exposure continues and the body’s cooling mechanisms begin to fail, the condition can progress to heat stroke, which is a medical emergency. In heat stroke, body temperature often rises above 104°F," Dr. Vaibhav Mishra, Senior Director & Head, CTVS, Max Super Speciality Hospital, told HealthandMe.
What may initially appear as confusion, disorientation, or irrelevant talking can rapidly worsen into:
Also read: Bundibugyo Ebola Cases Rise To 600 As Scientists Investigate Spillover Event
While it may be impossible to avoid rising temperatures, the focus should be on how much you can protect yourself. Experts suggest the following measures:
The India Meteorological Department (IMD) has warned of severe temperatures across several states.
"Heat wave to severe heat wave conditions likely to continue to prevail over northwest & central India during the week and over East India during the next 5 days," the IMD said, in its latest update on May 20.
It added that severe heat conditions will persist for at least the next 72 hours across Delhi-NCR, Rajasthan, Uttar Pradesh, Punjab, and Haryana. Temperatures in several cities are expected to touch 47°C to 48°C, with Banda currently emerging as the hottest place in the country.
© 2024 Bennett, Coleman & Company Limited